Genetic Steroid-Resistant Nephrotic Syndrome Overview

Beata S Lipska-Ziętkiewicz, MD, PhD

Created: August 26, 2021.

Summary

The purpose of this overview is to provide clinically relevant information regarding genetic steroid-resistant nephrotic syndrome (SRNS), strategies to establish the diagnosis, management, and genetic counseling.

The following are the goals of this overview.

Goal 1
Describe the clinical characteristics of genetic steroid-resistant nephrotic syndrome.

Goal 2
Review the genes known to be associated with genetic steroid-resistant nephrotic syndrome.

Goal 3
Provide an evaluation strategy to identify the cause of genetic steroid-resistant nephrotic syndrome in a proband (when possible).

Goal 4
Review phenocopies of genetic steroid-resistant nephrotic syndrome.

Goal 5
Review management of genetic steroid-resistant nephrotic syndrome.

Goal 6
Inform risk assessment and surveillance of at-risk relatives for early detection and treatment of genetic steroid-resistant nephrotic syndrome.
1. Clinical Characteristics of Genetic Steroid-Resistant Nephrotic Syndrome

The initial manifestation of nephrotic syndrome is severe proteinuria defined as presence of the following [Trautmann et al 2020]:

- Urine protein/creatinine ratio (UPCR) ≥200 mg/mmol (2 mg/mg) in the first morning void; OR 24-h urine sample ≥1000 mg/m²/day corresponding to 3+ or 4+ by urine dipstick
- Hypoalbuminemia (serum albumin <30 g/L)
- Edema

About 85% of nephrotic syndrome is steroid sensitive (SSNS), defined as complete remission of proteinuria following glucocorticoid treatment. SSNS will not be discussed further in this overview.

About 15% of nephrotic syndrome is steroid resistant (SRNS), defined as proteinuria that does not remit within four to six weeks of glucocorticoid treatment. About 50% of individuals with SRNS achieve sustained remission with intensified immunosuppressive treatment, whereas the rest have multi-drug resistance and progress to chronic kidney disease (CKD) and eventually to kidney failure.

**Non-genetic SRNS** is defined as SRNS that is not caused by alterations in a gene known to be associated with SRNS. In contrast to genetic SRNS, non-genetic SRNS has been postulated (but not yet confirmed) to be immune mediated and associated with circulating permeability factor(s) in the plasma.

Although most non-genetic SRNS is steroid resistant at the onset, a few individuals may initially respond to standard steroid therapy but subsequently demonstrate secondary steroid resistance. About 70% of individuals with non-genetic SRNS experience rapid post-transplantation recurrence of nephrotic syndrome in the graft [Mason et al 2020].

**Genetic SRNS** is defined as SRNS caused by a pathogenic variant (or pathogenic variants) in a gene that affects the establishment and maintenance of the glomerular filtration barrier. The glomerular filtration barrier comprises podocytes, the glomerular basement membrane, and fenestrated endothelial cells. All genetic SRNS can be corrected with renal transplantation.

In SRNS, about 30% of individuals with childhood-onset disease and 10%-15% of individuals with adult-onset disease have an underlying genetic alteration in one of the roughly 60 genes associated with genetic SRNS (see Section 2). Genetic SRNS can be either syndromic (when associated with additional signs and symptoms) (see Table 1) or nonsyndromic (when not associated with other manifestations) (see Table 2).

2. Causes of Genetic Steroid-Resistant Nephrotic Syndrome

Tables 1 and 2 (adapted from Table 1 in Preston et al [2019] and Table 3 in Trautmann et al [2020]) summarize the genes known to be associated with genetic steroid-resistant nephrotic syndrome (SRNS).

Table 1 lists genes associated with syndromic genetic SRNS and Table 2 lists genes associated with nonsyndromic genetic SRNS.

Identification of a genetic SRNS can be particularly useful in individuals with syndromic genetic SRNS (see Table 1) in which relevant extrarenal features may escape clinical detection or may arise later in the course of disease, such as hearing loss (associated with Alport syndrome and primary coenzyme Q₁₀ deficiency); Wilms tumor, gonadoblastoma, or gonadal dysgenesis (with WT1 disorder); or chronic motor and sensory polyneuropathy (associated with INF2-related Charcot-Marie-Tooth hereditary neuropathy).
Note: The following genes are listed in both Table 1 and Table 2 because they can be associated with syndromic genetic SRNS or with isolated, or apparently isolated, genetic SRNS: COL4A3/4/5, COQ8B (ADCK4), CRB2, INF2, LMX1B, and WT1. Some individuals who present with an apparently isolated renal phenotype may have extrarenal manifestations that are not appreciated until further clinical evaluation is prompted by the identification of a pathogenic variant (or pathogenic variants) in a gene known to be associated with syndromic genetic SRNS [Knoers et al 2021].

Table 1. Syndromic Genetic SRNS: Genes and Clinical Features

<table>
<thead>
<tr>
<th>Gene(s)</th>
<th>MOI</th>
<th>Syndrome / Features in Addition to SRNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALG1</td>
<td>AR</td>
<td>ALG1-CDG: microcephaly, neurologic involvement (seizures, neurologic deterioration, cerebral or cerebellar atrophy), skeletal, cardiac, hepatic, gastrointestinal, endocrine, coagulation abnormalities (See Congenital Disorder of N-Linked Glycosylation.)</td>
</tr>
<tr>
<td>ARHGDIA</td>
<td>AR</td>
<td>Seizures &amp; cortical blindness (OMIM 615244)</td>
</tr>
<tr>
<td>AVIL</td>
<td>AR</td>
<td>Microcephaly, short stature, retinal dystrophy, cataracts, deafness, &amp; DD (OMIM 618594)</td>
</tr>
<tr>
<td>CD151</td>
<td>AR</td>
<td>Pretibial bullous skin lesions, SNHL, bilateral lacrimal duct stenosis, nail dystrophy, &amp; thalassemia minor (OMIM 609057)</td>
</tr>
<tr>
<td>COL4A3</td>
<td>2</td>
<td>Alport syndrome: ocular abnormalities (anterior lenticulus, corneal &amp; retinal lesions), SNHL, leiomyomas (if large deletions include COL4A6)</td>
</tr>
<tr>
<td>COL4A4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>COQ2</td>
<td>COQ6</td>
<td>Primary coenzyme Q10 deficiency: neurologic involvement (encephalomyopathy, ataxia, seizures), DD, cognitive impairment, SNHL</td>
</tr>
<tr>
<td>COQ8B</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>CRB2</td>
<td>2</td>
<td>Prenatal-onset ventriculomegaly, seizures, renal corticomedullary cysts, cardiac &amp; congenital defects (OMIM 219730)</td>
</tr>
<tr>
<td>DGKE</td>
<td></td>
<td>C3 glomerulopathy</td>
</tr>
<tr>
<td>E2F3</td>
<td>AD</td>
<td>ID (whole-gene deletion) (OMIM 600427)</td>
</tr>
<tr>
<td>FAT1</td>
<td>AR</td>
<td>Neurologic involvement; dysmorphic features, colobomatous microphthalmia, renal tubular ectasia, hematuria</td>
</tr>
<tr>
<td>INF2</td>
<td>2</td>
<td>Peripheral neuropathy (distal muscle atrophy &amp; weakness), SNHL (See CMT Overview.)</td>
</tr>
<tr>
<td>ITGA3</td>
<td>AR</td>
<td>Epidermolysis bullosa, congenital interstitial lung disease (OMIM 614748)</td>
</tr>
<tr>
<td>ITGB4</td>
<td>AR</td>
<td>Epidermolysis bullosa w/pyloric atresia</td>
</tr>
<tr>
<td>LAGE3</td>
<td>XL</td>
<td>Galloway-Mowat syndrome 2: facial dysmorphism, microcephaly, CNS involvement (structural brain anomalies, seizures), optic nerve atrophy, DD, cognitive impairment, skeletal abnormalities, hiatus hernia (OMIM 301006)</td>
</tr>
<tr>
<td>LAMB2</td>
<td>AR</td>
<td>Pierson syndrome: ocular malformations (microcoria, cataracts, other lens or retinal abnormalities); neonatal hypotonia, DD, cognitive impairment (OMIM 609049)</td>
</tr>
<tr>
<td>LMX1B</td>
<td>2</td>
<td>Nail-patella syndrome: limb &amp; pelvic abnormalities (absent or hypoplastic patella, elbow abnormalities, iliac horns), absent or dystrophic nails &amp; distal digital abnormalities, eye abnormalities including glaucoma</td>
</tr>
<tr>
<td>MAFB</td>
<td>AD</td>
<td>Duane syndrome: a non-progressive limited horizontal eye movement accompanied by globe retraction</td>
</tr>
<tr>
<td>MAGI2</td>
<td>AR</td>
<td>± neurologic impairment (OMIM 617609)</td>
</tr>
<tr>
<td>Gene(s)</td>
<td>MOI</td>
<td>Syndrome / Features in Addition to SRNS</td>
</tr>
<tr>
<td>---------</td>
<td>-----</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td><strong>MT-TL1</strong></td>
<td>Mat</td>
<td><strong>MELAS:</strong> neurologic involvement (encephalomyopathy, seizures, stroke-like episodes), exercise intolerance, SNHL, retinopathy, diabetes mellitus, hypoparathyroidism, lactic acidosis</td>
</tr>
<tr>
<td><strong>MYH9</strong></td>
<td>AD</td>
<td><strong>MYH9-related disease:</strong> hematologic features present from birth consisting of platelet macrocytosis, thrombocytopenia, &amp; aggregates of the MYH9 protein in the cytoplasm of neutrophil granulocytes. Most affected individuals develop ≥1 additional extrahematologic manifestations including SNHL, renal disease, presenile cataracts, &amp;/or ↑ liver enzymes</td>
</tr>
<tr>
<td><strong>NUP107</strong></td>
<td>AR</td>
<td>Galloway-Mowat syndrome 7: facial dysmorphism, microcephaly, CNS involvement (structural brain anomalies, seizures), optic nerve atrophy, DD, cognitive impairment, skeletal abnormalities, hiatus hernia (OMIM 618348)</td>
</tr>
<tr>
<td><strong>NUP85</strong></td>
<td>AR</td>
<td>ID, short stature, microscopic hematuria (OMIM 618176)</td>
</tr>
<tr>
<td><strong>NUP205</strong></td>
<td>AR</td>
<td>Aortic abnormalities 6, 7</td>
</tr>
<tr>
<td><strong>NXF5</strong></td>
<td>XL</td>
<td>Heart block disorder 8</td>
</tr>
<tr>
<td><strong>OSGEP TP53RK TPRKB WDR73</strong></td>
<td>AR</td>
<td>Galloway-Mowat syndrome 3: Facial dysmorphism, microcephaly, CNS involvement (structural brain anomalies, seizures), optic nerve atrophy, DD, cognitive impairment, skeletal abnormalities, hiatus hernia (OMIM PS251300)</td>
</tr>
<tr>
<td><strong>PAX2</strong></td>
<td>AD</td>
<td><strong>PAX2 disorder:</strong> eye abnormalities (retinal coloboma, optic disc dysplasia), congenital anomalies of the kidney and urinary tract, renal cysts, renal dysplasia/hypoplasia</td>
</tr>
<tr>
<td><strong>PDSS2</strong></td>
<td>AR</td>
<td><strong>Primary coenzyme Q10 deficiency:</strong> neurologic involvement (encephalomyopathy, ataxia, seizures), DD, cognitive impairment, SNHL</td>
</tr>
<tr>
<td><strong>PMM2</strong></td>
<td>AR</td>
<td><strong>PMM2-CDG:</strong> microcephaly, neurologic involvement (seizures, neurologic deterioration, cerebral or cerebellar atrophy); skeletal, cardiac, hepatic, gastrointestinal, endocrine, coagulation abnormalities</td>
</tr>
<tr>
<td><strong>SCARB2</strong></td>
<td>AR</td>
<td><strong>Action myoclonus – renal failure syndrome:</strong> Neurologic symptoms (tremor, action myoclonus, tonic-clonic seizures, later ataxia &amp; dysarthria), sensorimotor peripheral neuropathy, SNHL, dilated cardiomyopathy</td>
</tr>
<tr>
<td><strong>SGPL1</strong></td>
<td>AR</td>
<td><strong>Sphingosine phosphate lyase insufficiency syndrome:</strong> varying combinations of primary adrenal insufficiency (± mineralocorticoid deficiency), testicular insufficiency, ichthyosis, neurologic involvement (DD, seizures, ataxia), immunodeficiency, skeletal abnormalities</td>
</tr>
<tr>
<td><strong>SMARCAL1</strong></td>
<td>AR</td>
<td><strong>Schimke immunoosseous dysplasia:</strong> spondyloepiphyseal dysplasia resulting in short stature; T-cell deficiency</td>
</tr>
</tbody>
</table>
Table 1. continued from previous page.

<table>
<thead>
<tr>
<th>Gene(s) 1</th>
<th>MOI</th>
<th>Syndrome / Features in Addition to SRNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT1 2</td>
<td>AD</td>
<td>WT1 disorder: disorders of testicular development (± abnormalities of external genitalia &amp;/or müllerian structures) &amp; Wilms tumor; congenital anomalies of kidney &amp; urinary tract, diaphragmatic hernia</td>
</tr>
</tbody>
</table>

AD = autosomal dominant; AR = autosomal recessive; CDG = congenital disorder of glycosylation; CKD = chronic kidney disease; CMT = Charcot-Marie-Tooth disease; CNS = central nervous system; DD = developmental delay; ID = intellectual disability; Mat = maternal; MELAS = mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MOI = mode of inheritance; SNHL = sensorineural hearing loss; SRNS = steroid-resistant nephrotic syndrome; XL = X-linked
1. Genes are listed alphabetically
2. Also associated with nonsyndromic SRNS
3. Nozu et al [2017]
4. C3 glomerulopathy is a complex genetic disorder that is rarely inherited in a simple mendelian fashion. Multiple affected persons within a single nuclear family are reported only occasionally, with both autosomal dominant and autosomal recessive inheritance being described.
5. Lahrouchi et al [2019]
7. Preliminary data suggest that NUP205 may also be associated with nonsyndromic genetic SRNS [Author, unpublished data].
8. Esposito et al [2013]

Table 2. Nonsyndromic Genetic SRNS: Genes and Distinguishing Clinical Features

<table>
<thead>
<tr>
<th>Gene 1</th>
<th>MOI</th>
<th>% of All Nonsyndromic SRNS</th>
<th>Typical Age at Onset of SRNS</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTN4</td>
<td>AD</td>
<td>~1%</td>
<td>Usually late (adult)</td>
<td>OMIM 603278</td>
</tr>
<tr>
<td>ANKFY1</td>
<td>AD</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 607927</td>
</tr>
<tr>
<td>ANLN</td>
<td>AD</td>
<td>&lt;1%</td>
<td>Mainly late (adult)</td>
<td>OMIM 616032</td>
</tr>
<tr>
<td>APOL1</td>
<td>Risk allele</td>
<td>No data 2</td>
<td>↑ susceptibility in African Americans, Hispanic Americans, &amp; persons of African descent</td>
<td>OMIM 612551</td>
</tr>
<tr>
<td>ARHGAP24</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Mainly late (adult)</td>
<td>OMIM 610586</td>
</tr>
<tr>
<td>CD2AP</td>
<td>AD/AR</td>
<td>&lt;1%</td>
<td>Childhood &amp; adult</td>
<td>OMIM 607832</td>
</tr>
<tr>
<td>COL4A3</td>
<td>XL</td>
<td>~10%-30% (esp if onset in/after 2nd decade)</td>
<td>Mainly late (adolescent &amp; adult)</td>
<td>Gast et al [2016]</td>
</tr>
<tr>
<td>COL4A4</td>
<td>XL</td>
<td>~10%-30% (esp if onset in/after 2nd decade)</td>
<td>Mainly late (adolescent &amp; adult)</td>
<td>Gast et al [2016]</td>
</tr>
<tr>
<td>COL4A5</td>
<td>XL</td>
<td>~10%-30% (esp if onset in/after 2nd decade)</td>
<td>Mainly late (adolescent &amp; adult)</td>
<td>Gast et al [2016]</td>
</tr>
<tr>
<td>COQ8B (ADCK4)</td>
<td>AR</td>
<td>3%-5%</td>
<td>Childhood &amp; adult</td>
<td>OMIM 615573</td>
</tr>
<tr>
<td>CRB2</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 609720</td>
</tr>
<tr>
<td>GAPVD1</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 611714</td>
</tr>
<tr>
<td>INF2</td>
<td>AD</td>
<td>3%</td>
<td>Mainly late (adolescent &amp; adult)</td>
<td>OMIM 613237</td>
</tr>
<tr>
<td>LAMA5</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 601033</td>
</tr>
<tr>
<td>LMX1B</td>
<td>AD</td>
<td>3%-5% (esp if onset in/after 2nd decade)</td>
<td>Mainly late (adolescent &amp; adult)</td>
<td>OMIM 256020</td>
</tr>
<tr>
<td>MYO1E</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 614131</td>
</tr>
<tr>
<td>NPHS1</td>
<td>AR</td>
<td>10%-20% (≤50% in CNS)</td>
<td>CNS (Finnish type) or childhood SRNS</td>
<td>OMIM 602716</td>
</tr>
</tbody>
</table>
Table 2. continued from previous page.

<table>
<thead>
<tr>
<th>Gene</th>
<th>MOI</th>
<th>% of All Nonsyndromic SRNS</th>
<th>Typical Age at Onset of SRNS</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPHS2</td>
<td>AR</td>
<td>20%-30% (≤40% in CNS)</td>
<td>CNS or childhood &amp; adult SRNS</td>
<td>OMIM 600995</td>
</tr>
<tr>
<td>NUP133</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 607613</td>
</tr>
<tr>
<td>NUP160</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 618178</td>
</tr>
<tr>
<td>NUP93</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 616892</td>
</tr>
<tr>
<td>PLCE1</td>
<td>AR</td>
<td>3%</td>
<td>CNS or childhood SNRS</td>
<td>OMIM 610725</td>
</tr>
<tr>
<td>PTPRO</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 614196</td>
</tr>
<tr>
<td>TBC1D8B</td>
<td>XL</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 301028</td>
</tr>
<tr>
<td>TRPC6</td>
<td>AD</td>
<td>3%</td>
<td>Childhood &amp; adult SRNS</td>
<td>OMIM 603965</td>
</tr>
<tr>
<td>TTC21B</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood &amp; adult Nephronophthisis</td>
<td></td>
</tr>
<tr>
<td>WT1</td>
<td>AD</td>
<td>10%-20%</td>
<td>CNS or childhood &amp; adult SRNS</td>
<td>WT1 Disorder</td>
</tr>
<tr>
<td>XPO5</td>
<td>AR</td>
<td>&lt;1%</td>
<td>Childhood</td>
<td>OMIM 607845</td>
</tr>
</tbody>
</table>

AD = autosomal dominant; AR = autosomal recessive; CNS = congenital nephrotic syndrome; MOI = mode of inheritance; SRNS = steroid-resistant nephrotic syndrome; XL = X-linked

1. Genes are listed alphabetically
2. 13% of African Americans have the APOL1 high-risk genotype (2 risk alleles) and these individuals have a 3- to 30-fold increased risk of various forms of kidney disease; the frequency in individuals of European ancestry is unknown [Friedman & Pollak 2020].
3. Also associated with syndromic genetic SRNS.
4. Lipska-Ziętkiewicz & Schaefer [2019]
5. Preliminary data suggest that NUP93 may also be associated with syndromic genetic SRNS [Author, unpublished data].

Nomenclature

Genetic SRNS may also be referred to as "hereditary SRNS" or "monogenic SRNS."

Nonsyndromic genetic SRNS may also be referred to as "hereditary podocytopathy/glomerulopathy."

Glomerulopathy is the preferred term as a subset of individuals with a hereditary podocytopathy never receive steroids, and, thus, their renal disease cannot be classified as steroid resistant.

In the context of genetic SRNS, use of the terms "idiopathic SRNS" and "primary SRNS" is controversial as these terms may imply absence of molecularly confirmed diagnosis.

3. Evaluation Strategies to Identify the Cause of Genetic Steroid-Resistant Nephrotic Syndrome in a Proband

Establishing a specific cause of genetic steroid-resistant nephrotic syndrome usually involves a medical history, physical examination, laboratory testing, family history, and genomic/genetic testing.

The age at first disease manifestation and the rate of chronic kidney disease (CKD) progression will strongly depend on the gene affected and the type of causative pathogenic variant.

- Variants in LAMB2, NPHS1, NPHS2, and WT1 account for >80% of all congenital nephrotic syndrome. See Tables 1 and 2.
- Variants in INF2, TRPC6, and the genes encoding collagen IV (COL4A3, COL4A4, and COL4A5) are the leading causes of adult-onset SRNS.
**Medical history.** A detailed medical history for renal and extrarenal manifestations should be obtained wherever possible. Possible extrarenal manifestation(s) in individuals with syndromic genetic SRNS are included Table 1.

**Physical examination.** Clinical examination should be performed to identify the possible extrarenal manifestations of syndromic genetic SRNS (Table 1).

**Family history.** A three-generation family history should be taken, with attention to parental consanguinity and to relatives with manifestations of SRNS or other renal disease with their age at onset, clinical course (including response to medications), renal function, and documentation of relevant findings through direct examination or review of medical records (including results of molecular genetic testing and/or renal biopsy). Absence of a family history of such findings does not preclude the possibility of genetic SRNS.

**Molecular genetic testing** can include a combination of gene-targeted testing (single-gene testing or multigene panel) and comprehensive genomic testing (exome sequencing). Gene-targeted testing requires the clinician to hypothesize which gene(s) are likely involved, whereas genomic testing does not.

- **Single-gene testing** can be considered if clinical findings and/or family history indicate that pathogenic variants in a particular gene associated with genetic syndromic SRNS are most likely (see Table 1).

- **A multigene panel** that includes some or all of the genes listed in Tables 1 and 2 is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. Some panels may not include newly discovered and/or rare genes associated with genetic SRNS. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

- **Comprehensive genomic testing** (which does not require the clinician to determine which gene[s] are likely involved) may be considered. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

### 4. Phenocopies of Genetic Steroid-Resistant Nephrotic Syndrome

**Table 3. Phenocopies of Genetic SRNS Usually Presenting As Persistent Proteinuria**

<table>
<thead>
<tr>
<th>Gene</th>
<th>MOI</th>
<th>Syndrome / Phenotype</th>
<th>Additional Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFH</td>
<td>AD Polygenic</td>
<td>Genetic atypical hemolytic-uremic syndrome (aHUS)</td>
<td>Thrombocytopenia 2</td>
</tr>
<tr>
<td></td>
<td>Complex 3</td>
<td>C3 glomerulopathy</td>
<td>Membranoproliferative glomerulonephritis</td>
</tr>
<tr>
<td>CLCN5</td>
<td>XL</td>
<td>Dent disease 1: ± hypercalciuria &amp; nephrolithiasis</td>
<td>LMW proteinuria. Other features may incl rickets or osteomalacia, growth restriction/short stature.</td>
</tr>
<tr>
<td>CUBN</td>
<td>AR</td>
<td>Albuminuria, megaloblastic anemia ± epilepsy (OMIM 618884) 4</td>
<td>Imerslund-Gräsbeck syndrome 1 (OMIM 261100), intestinal malabsorption of vitamin B₁₂, LMW proteinuria</td>
</tr>
</tbody>
</table>
Table 3. continued from previous page.

<table>
<thead>
<tr>
<th>Gene</th>
<th>MOI</th>
<th>Syndrome / Phenotype</th>
<th>Additional Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>FN1</td>
<td>AD</td>
<td>Fibronectin glomerulopathy (OMIM 601894)</td>
<td>Proteinuria, type IV renal tubular acidosis, microscopic hematuria</td>
</tr>
<tr>
<td>LCAT</td>
<td>AR</td>
<td>Norum disease (Lecithin:cholesterol acyltransferase deficiency) (OMIM 245900)</td>
<td>Corneal opacities, target cell hemolytic anemia, proteinuria</td>
</tr>
<tr>
<td>LMNA</td>
<td>AD</td>
<td>Familial partial lipodystrophy (OMIM 151660)</td>
<td>Abnormal subcutaneous adipose tissue distribution, diabetes mellitus, hypertension</td>
</tr>
<tr>
<td>MMACHC</td>
<td>AR</td>
<td>Cobalamin C deficiency (See Disorders of Intracellular Cobalamin Metabolism.)</td>
<td>TMA, neurologic involvement; cytopenia; thromboembolism</td>
</tr>
<tr>
<td>NEU1</td>
<td>AR</td>
<td>Neuraminidase deficiency (OMIM 256550)</td>
<td>Progressively severe mucopolysaccharidosis-like phenotype (coarse faces, dysostosis multiplex, hepatosplenomegaly), progressive neurologic degeneration, childhood nephrotic syndrome, macular cherry-red spots, &amp; DD/ID.</td>
</tr>
<tr>
<td>NPHP4</td>
<td>AR</td>
<td>Isolated nephronophthisis (NPH)</td>
<td>~80%-90% of persons w/NPH phenotype have no extrarenal features.</td>
</tr>
<tr>
<td>OCRL</td>
<td>XL</td>
<td>Dent disease 2</td>
<td>Proximal tubule dysfunction &amp; LMW proteinuria, assoc w/ hypercalciuria, nephrolithiasis, nephrocalcinosis, &amp; progressive renal failure</td>
</tr>
<tr>
<td>ZMPSTE24</td>
<td>AR</td>
<td>Mandibuloacral dysplasia (OMIM 608612)</td>
<td>Generalized lipoatrophy, postnatal growth retardation, dysmorphic features, mandibular &amp; clavicular hypoplasia, other skeletal &amp; dental abnormalities, restrictive dermopathy</td>
</tr>
</tbody>
</table>

AD = autosomal dominant; AR = autosomal recessive; CKD = chronic kidney disease; DD = developmental delay; ID = intellectual disability; LMW = low-molecular-weight; MOI = mode of inheritance; SRNS = steroid-resistant nephrotic syndrome; TMA = thrombotic microangiopathy; XL = X-linked

1. Genes are listed alphabetically
2. Simultaneous kidney & liver transplantation in young children w/CFH-aHUS may correct the genetic defect & prevent disease recurrence.
3. C3 glomerulopathy (C3G) is a complex genetic disorder that is rarely inherited in a simple mendelian fashion. In most persons with C3G, inheritance is complex and incompletely understood. For these reasons, recurrence risk to family members is not known but likely very low.
4. C-terminal variants associate with chronic proteinuria and normal renal function [Bedin et al 2020].

5. Management of Genetic Steroid-Resistant Nephrotic Syndrome

In 2020 the International Pediatric Nephrology Association developed comprehensive clinical practice recommendations for the diagnosis and management of SRNS in children [Trautmann et al 2020].

See also the detailed genetic and clinical guidelines for management of congenital nephrotic syndrome [Lipska-Ziętkiewicz et al 2020, Boyer et al 2021].

Once the diagnosis of SRNS is established, ineffective prednisolone/prednisone treatment should be avoided. Instead affected individuals should be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) to reduce proteinuria.

While recent recommendations also suggest withholding calcineurin inhibitors and other immunosuppressive agents in individuals with evidence for genetic SRNS, the final decision should be made on an individual basis (for details see Trautmann et al [2020]).
Clinical management also includes the following:

- Prompt detection and treatment of hypertension
- Cautious use of diuretics, vitamin D, and thyroid hormone substitution
- Conservative management of chronic kidney disease (CKD)
- Renal replacement therapy including preemptive transplantation in selected disorders (e.g., WT1 disorder).

### 6. Risk Assessment and Surveillance of At-Risk Relatives for Early Detection and Treatment of Genetic Steroid-Resistant Nephrotic Syndrome

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Screening of asymptomatic first-degree family members (see Surveillance for At-Risk Relatives) of an individual with genetic steroid-resistant nephrotic syndrome (SRNS) can allow early detection of genetic SRNS, inform the indication for and frequency of subsequent screening, facilitate prompt initiation of treatment, and thereby improve long-term outcome [Trautmann et al 2020].

Clarification of the genetic status of first-degree family members can also help to identify potential organ donors. (Note: Molecular genetic testing for the familial pathogenic variant is obligatory for genetic SRNS with autosomal dominant transmission and in certain entities with significant intra- and interfamilial variability and incomplete or age-dependent penetrance [e.g., genetic SRNS associated with pathogenic variants in COL4A3/4/5, NPHS2, or WT1]).

Note: Given the complexity of the genetics and surveillance recommendations for genetic SRNS, health care providers should consider referring at-risk asymptomatic relatives to a nephrology genetics center or a genetic counselor specializing in nephrology genetics (see NSGC - Find a Genetic Counselor or ABGC Find a Certified Genetic Counselor search tools).

**Genetic risk assessment.** Genetic SRNS can be inherited in an autosomal recessive, autosomal dominant (e.g., WT1-related SRNS), or, rarely, X-linked (TBC1D8B-related SRNS) manner. A basic view of autosomal recessive and autosomal dominant inheritance and risk assessment and surveillance for at-risk relatives of an individual with genetic SRNS is presented below.

If a proband has a specific genetic syndrome associated with SRNS (e.g., WT1 disorder, Alport syndrome, primary coenzyme Q₁₀ deficiency, Schimke immunooosseous dysplasia, or Charcot-Marie-Tooth hereditary neuropathy), counseling for that condition is indicated (see Table 1).

### Autosomal Recessive Inheritance – Risk to Family Members

**Parents of a proband**

- The parents of an affected child are obligate heterozygotes (i.e., presumed to be carriers of one autosomal recessive genetic SRNS-causing pathogenic variant based on family history).
- Molecular genetic testing of the parents for the pathogenic variants identified in the proband is recommended to confirm that both parents are heterozygous for a causative pathogenic variant and to
allow reliable recurrence risk assessment. If a pathogenic variant is detected in only one parent, the following possibilities should be considered:

- One of the pathogenic variants identified in the proband occurred as a *de novo* event in the proband or as a postzygotic *de novo* event in a mosaic parent [Jónsson et al 2017].
- Uniparental isodisomy for the parental chromosome with the pathogenic variant resulted in homozygosity for the pathogenic variant in the proband.

- In some families, a parent of the proband is found to have biallelic genetic SRNS-causing pathogenic variants (rather than a heterozygous pathogenic variant). This is more likely to occur in families segregating a relatively common non-neutral variant such as the p.Arg229Gln *NPHS2* variant, which has a carrier frequency of 3% in the general multiethnic population, and carrier frequencies of 7% and 0.01% in Finnish and East Asian populations respectively. Note: A parent found to have biallelic SRNS-causing pathogenic variants is at risk of developing genetic SRNS later in life.
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing autosomal recessive genetic SRNS. A parent who is heterozygous for autosomal recessive genetic SRNS may be able to serve as a kidney donor.

**Sibs of a proband**

- If both parents are known to be heterozygous for an autosomal recessive SRNS-causing pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder. A sib who is heterozygous for autosomal recessive genetic SRNS may be able to serve as a kidney donor.

**Offspring of a proband.** The offspring of an individual with autosomal recessive genetic SRNS are obligate heterozygotes (carriers) for a pathogenic variant in an SRNS-causing pathogenic variant.

**Other family members.** Each sib of the proband’s parents is at a 50% risk of being a carrier of an autosomal recessive SRNS-causing pathogenic variant.

**Carrier Detection**

Carrier testing for at-risk relatives requires prior identification of the autosomal recessive SRNS-causing pathogenic variants in the family.

**Autosomal Dominant Inheritance – Risk to Family Members**

**Parents of a proband**

- Some individuals diagnosed with autosomal dominant genetic SRNS have an affected parent. The frequency of probands with an affected parent is highest in individuals with a heterozygous pathogenic variant in *COL4A3, COL4A4, COL4A5,* or *INF2.*
- Most individuals diagnosed with autosomal dominant genetic SRNS have the disorder as the result of a *de novo* pathogenic variant.
- If the proband appears to be the only affected family member (i.e., a simplex case), molecular genetic testing is recommended for the parents of the proband to confirm their genetic status and to allow reliable recurrence risk counseling. Note: Molecular genetic testing is obligatory for relatives considering organ donation.
- If the pathogenic variant identified in the proband is not identified in either parent, the following possibilities should be considered:
  - The proband has a *de novo* pathogenic variant. Note: A pathogenic variant is reported as "*de novo*" if: (1) the pathogenic variant found in the proband is not detected in parental DNA; and (2) parental
identity testing has confirmed biological maternity and paternity. If parental identity testing is not performed, the variant is reported as “assumed de novo” [Richards et al 2015].
- The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.
- The family history of some individuals diagnosed with an autosomal dominant genetic SRNS may appear to be negative because of failure to recognize the disorder in family members, reduced penetrance, and/or early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has demonstrated that neither parent is heterozygous for the pathogenic variant identified in the proband.

**Sibs of a proband.** The risk to the sibs of the proband depends on the clinical/genetic status of the proband’s parents:
- If a parent of the proband is affected and/or is known to have the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.
- If the proband has a known genetic SRNS-related pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is estimated to be 1% because of the possibility of parental germline mosaicism [Rahbari et al 2016].
- If the parents have not been tested for the pathogenic variant identified in the proband but are clinically unaffected, the risk to the sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for autosomal dominant genetic SRNS because of the possibility of reduced penetrance in a heterozygous parent or the possibility of parental germline mosaicism.

**Offspring of a proband.** Each child of an individual with autosomal dominant SRNS has a 50% chance of inheriting the genetic SRNS-causing pathogenic variant.

**Other family members.** The risk to other family members depends on the status of the proband’s parents: if a parent has the genetic SRNS-causing pathogenic variant, his or her family members may be at risk.

**Surveillance of At-Risk Relatives for Early Detection and Treatment of Genetic Steroid-Resistant Nephrotic Syndrome**

**For early diagnosis and treatment**
- First degree relatives, including sibs, should be offered urine analysis for proteinuria. This testing should be offered to at-risk family members as soon as possible and should not be delayed pending molecular confirmation that the proband has genetic SRNS.

Family members found to have proteinuria should undergo detailed clinical evaluation by a nephrologist to either confirm a diagnosis of genetic SRNS or detect any other cause of proteinuria (see Section 4). Family members who do not have proteinuria are still at risk for genetic SRNS (as genetic SRNS is characterized by variable expressivity and incomplete and/or age-dependent penetrance) and should undergo genetic testing once a molecular diagnosis is established in the proband.
- Once the genetic SRNS-causing pathogenic variant(s) have been identified in the proband, it is appropriate to clarify the genetic status of at-risk relatives to identify individuals with the familial pathogenic variant(s) as early as possible.

Early identification of a genetic predisposition may result in successful delay of disease progression, not only by avoiding ineffective therapies and their substantial side effects, but also by the following: initiation
of treatment with RAASi to reduce proteinuria; prompt detection and treatment of hypertension; cautious use of diuretics, vaccination, vitamin D, and thyroid hormone substitution; and early start of targeted treatment such as ubiquinone supplementation in COQ10 deficiency.

Early intervention may also include surveillance for extrarenal manifestations (e.g., endocrinologic, oncologic, immune, or neurologic; see Table 1 for particular diagnoses and associated phenotypes) [Trautmann et al 2020].

Members of the family found negative on genetic testing may be discharged from surveillance and are no longer considered at increased risk for genetic SRNS.

For family members being evaluated for living-related kidney donation

- Any relative who is a potential kidney donor should undergo molecular genetic testing to clarify his/her genetic status. Screening of the potential donor with molecular genetic testing is obligatory for families segregating autosomal dominant or X-linked genetic SRNS and in certain entities with significant intra- and interfamilial variability and incomplete or age-dependent penetrance (e.g., genetic SRNS associated with pathogenic variants in WT1, COL4A3/4/5, or NPHS2).
- Family members who are found to have a pathogenic variant associated with autosomal dominant or X-linked genetic SRNS cannot serve as kidney donors regardless of clinical status [Lipska-Ziętkiewicz et al 2020, Trautmann et al 2020].
- Individuals who are heterozygous for a pathogenic variant associated with autosomal recessive genetic SRNS and individuals who do not have the familial genetic SRNS-related pathogenic variant can be evaluated further as possible kidney donors.

Resources

*GeneReviews* staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. *GeneReviews* is not responsible for the information provided by other organizations. For information on selection criteria, click here.

- **American Kidney Fund**
  
  11921 Rockville Pike
  
  Suite 300
  
  Rockville MD 20852
  
  **Phone:** 866-300-2900
  
  **Email:** helpline@kidneyfund.org
  
  www.kidneyfund.org

- **European Rare Kidney Disease Reference Network (ERKNet)**
  
  Heidelberg
  
  Germany
  
  **Phone:** 49-6221-56-2349
  
  **Fax:** 49-6221-56-5166
  
  **Email:** contact@erknet.org
  
  www.erknet.org

- **Kidney Foundation of Canada**
310-5160 Decarie Boulevard
Montreal Ontario H3X 2H9
Canada
Phone: 800-361-7494 (toll-free); 514-369-4806
Fax: 514-369-2472
Email: info@kidney.ca
www.kidney.ca

- NephCure Kidney International
  Phone: 866-NephCure; 866-637-4287
  Email: info@nephcure.org
  nephcure.org

- Nephrotic Syndrome Study Network (NEPTUNE)
  As a research consortium of physician scientists at 26 sites in the United States and Canada, along with
  patient advocacy groups NephCure Kidney International and the Halpin Foundation, NEPTUNE strives to
  bring the latest advances in research to patients diagnosed with Focal Segmental Glomerulosclerosis (FSGS),
  Minimal Changes Disease (MCD), and Membranous Nephropathy (MN) with an overarching goal of
  utilizing precision medicine for rare diseases.
  Phone: 734-615-5020
  Email: NEPTUNE-STUDY@umich.edu
  www.neptune-study.org

- PodoNet Registry
  The PodoNet Registry explores the demographics, causes and prognosis of patients with congenital and steroid
  resistant nephrotic syndrome.
  Clinical, Genetic and Experimental Research into Hereditary Disease of the Podocyte
  PodoNet

Chapter Notes

Author Notes
Beata S Lipska-Ziętkiewicz is the genetic coordinator at PodoNet (www.escapenet.eu/researchers/beata-lipska-
zietskiewicz), one of the largest international registries of steroid-resistant nephrotic syndrome. She is a member
of the Molecular Diagnostics Task Force and co-chair of the Hereditary Glomerulopathies Working Group for
the European Rare Kidney Disease Reference Network (ErkNet).

Revision History
- 26 August 2021 (bp) Review posted live
- 11 January 2021 (blz) Original submission

References


License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2021 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.